Nurix Therapeutics, Inc. $NRIX Shares Sold by Candriam S.C.A.

Key Points

• Candriam S.C.A. reduced its stake in Nurix Therapeutics by 7.2%, selling 45,695 shares and retaining 588,931 shares worth approximately $6.99 million.
• Insiders at Nurix Therapeutics, including CFO Houte Hans Van, sold shares, resulting in the CFO reducing his holdings by 13.20%.
• Analysts maintain a positive outlook on Nurix, with the average target price at $28.87 and several firms giving "buy" ratings despite some recent price target adjustments.

Candriam S.C.A. lessened its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 7.2% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 588,931 shares of the company's stock after selling 45,695 shares during the quarter. Candriam S.C.A. owned 0.77% of Nurix Therapeutics worth $6,997,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. ARK Investment Management LLC increased its position in Nurix Therapeutics by 4.0% during the 1st quarter. ARK Investment Management LLC now owns 1,590,910 shares of the company's stock worth $18,900,000 after purchasing an additional 60,617 shares in the last quarter. Hussman Strategic Advisors Inc. acquired a new stake in Nurix Therapeutics during the 1st quarter worth approximately $499,000. RA Capital Management L.P. acquired a new stake in Nurix Therapeutics during the 4th quarter worth approximately $25,120,000. Ensign Peak Advisors Inc increased its position in Nurix Therapeutics by 108.2% during the 4th quarter. Ensign Peak Advisors Inc now owns 374,673 shares of the company's stock worth $7,059,000 after purchasing an additional 194,673 shares in the last quarter. Finally, Velan Capital Investment Management LP acquired a new stake in Nurix Therapeutics during the 4th quarter worth approximately $1,844,000.

Insider Activity at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 5,402 shares of the stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $11.03, for a total transaction of $59,584.06. Following the completion of the transaction, the chief financial officer directly owned 35,512 shares in the company, valued at approximately $391,697.36. This represents a 13.20% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Gwenn Hansen sold 4,308 shares of the stock in a transaction that occurred on Wednesday, July 30th. The shares were sold at an average price of $12.01, for a total value of $51,739.08. Following the transaction, the insider owned 69,023 shares of the company's stock, valued at approximately $828,966.23. This trade represents a 5.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 14,014 shares of company stock valued at $163,014. Company insiders own 7.40% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on NRIX. Needham & Company LLC reissued a "buy" rating and set a $27.00 target price on shares of Nurix Therapeutics in a research report on Tuesday, April 29th. Morgan Stanley set a $16.00 price target on Nurix Therapeutics and gave the stock an "equal weight" rating in a report on Tuesday, July 15th. Oppenheimer restated an "outperform" rating and issued a $30.00 price target (down previously from $32.00) on shares of Nurix Therapeutics in a report on Thursday, July 31st. UBS Group decreased their price target on Nurix Therapeutics from $30.00 to $26.00 and set a "buy" rating for the company in a report on Thursday, July 10th. Finally, Stephens restated an "overweight" rating and issued a $30.00 price target on shares of Nurix Therapeutics in a report on Thursday, July 10th. Thirteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $28.87.

Nurix Therapeutics Trading Up 1.3%

Nurix Therapeutics stock opened at $9.65 on Friday. The stock has a market cap of $737.74 million, a P/E ratio of -3.70 and a beta of 2.14. The stock has a 50 day moving average of $11.44 and a 200-day moving average of $12.17. Nurix Therapeutics, Inc. has a 52 week low of $8.18 and a 52 week high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its earnings results on Wednesday, July 9th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.27. The company had revenue of $44,056 billion during the quarter, compared to analysts' expectations of $16.26 million. Nurix Therapeutics had a negative return on equity of 45.26% and a negative net margin of 234.57%. As a group, equities analysts predict that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Want to see what other hedge funds are holding NRIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.